Accelerate Diagnostics Inc

Accelerate Diagnostics Inc(AXDX)股票分析

$0.034

-0.021 (-61.36%)收盤時

Loading chart…
High
0.080
Open
0.080
VWAP
0.05
Vol
67.48M
Mkt Cap
27.15M
Low
0.031
Amount
3.26M
EV/EBITDA, TTM
-2.10

Accelerate Diagnostics, Inc. is an in-vitro diagnostics company. The Company is engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. Its in-vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk.

Analyst Ratings (4)

Buy
4 Buy
0 Hold
0 Sell
Current: 0.03
最低
平均
最高

Craig-Hallum

2024-04-01

目標價

$1

Hold

Craig-Hallum

2022-03-09

目標價

$50

Hold

BTIG

2020-10-08

目標價

Hold

JP Morgan

2019-09-27

目標價

$160

Sell

JP Morgan

2018-11-07

目標價

$160

Hold

估值指標

The current forward P/E ratio for Accelerate Diagnostics Inc (AXDX) is -0.53, compared to its 5-year average forward P/E of -1.83.

Forward P/E

Fair
5Y Average P/E
-1.83
Current P/E
-0.53
高估
-0.41
低估
-3.25

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-1.75
Current EV/EBITDA
-2.10
高估
0.76
低估
-4.26

Forward P/S

Fair
5Y Average P/S
6.97
Current P/S
2.30
高估
13.89
低估
0.06

事件時間軸

2025-05-08 (ET)

09:03:49

Accelerate Diagnostics files for Chapter 11 protection, agrees to sell assets

2025-04-15 (ET)

17:42:50

Accelerate Diagnostics board forms committee to exlore strategic alternatives

2025-03-21 (ET)

13:55:25

Accelerate Diagnostics submits WAVE system for FDA 510(k) clearance

08:32:35

Accelerate Diagnostics reports Q4 EPS (38c)

2024-09-30 (ET)

09:27:15

Accelerate Diagnostics announces FDA clearance of Accelerate Arc system

資訊

AXDX FAQ — answered by Alphio AI

Accelerate Diagnostics, Inc. is an in-vitro diagnostics company. The Company is engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. Its in-vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

4 analysts cover AXDX: 4 rate it Buy, 0 Hold and 0 Sell.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始